Nevena Velimirovici
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nevena Velimirovici has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Todor
Faculty of Medicine and Pharmacy, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca, 8 Victor Babeș Ave., 400347 Cluj-Napoca, Romania
1 shared publication - Andrei Ghiorghitoiu
Department of Orthopedics and Trauma, “Victor Babes” University of Medicine and Pharmacy, No 2 Eftimie Murgu Square, 300041 Timisoara, Romania
1 shared publication - Bogdan Deleanu
Department of Orthopedics, “Victor Babes” University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania
1 shared publication - Cristina Tudoran
Center of Molecular Research in Nephrology and Vascular Disease, Faculty of the of Medicine, “Victor Babes” University of Medicine and Pharmacy, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania
1 shared publication - Horia Haragus
Department of Orthopedics and Trauma, “Victor Babes” University of Medicine and Pharmacy, No 2 Eftimie Murgu Square, 300041 Timisoara, Romania
1 shared publication - Oana Suciu
Department of Rehabilitation, Physical Medicine and Rheumatology, Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
1 shared publication
Latest Publications
- Open Access
- 2 December 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (23) , 8617
Platelet Aggregation Inhibitors and Anticoagulants Delay Surgery for Hip Fractures
Background: we aimed to analyze the influence of antithrombotic medication in delaying surgery for fragility hip fractures; Method: a total of 312 consecutive hip fracture cases over 55 years who underwent surgery in our Orthopedic Clinic; Results: of these, 90 patients received chronic antithrombotic medication. There were no differences between the medicated group and controls (n = 222) regarding age, gender, type of fracture and haemoglobin at admittance. However, median time to surgery was significantly longer in the medicated group: 4(3–6) days compared to 2(1–4) (p < 0.0001). By type of medication, time to surgery was: 3(1–4) days for acetylsalicylic acid (n = 44), 6(5.25–7.75) days for clopidogrel (n = 15), 4.5(4–7) days for acenocoumarin (n = 18) and 5(4–7.25) days for novel direct oral anticoagulants (n = 13). The Charlson comorbidity index was significantly higher in the medicated group: 5 [4–5] versus 4 [3–5]. There were no differences in transfusions except for fresh frozen plasma, which was administered more in the medicated patients; Conclusions: the prevalence of platelet aggregation inhibitors and anticoagulant use among fragility hip fracture patients is high, with almost a third using some form of antithrombotic medication. This may significantly lengthen time to surgery.
- 2 December 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (23) , 8617
Open AccessPlatelet Aggregation Inhibitors and Anticoagulants Delay Surgery for Hip Fractures
Background: we aimed to analyze the influence of antithrombotic medication in delaying surgery for fragility hip fractures; Method: a total of 312 consecutive hip fracture cases over 55 years who underwent surgery in our Orthopedic Clinic; Results: of these, 90 patients received chronic antithrombotic medication. There were no differences between the medicated group and controls (n = 222) regarding age, gender, type of fracture and haemoglobin at admittance. However, median time to surgery was significantly longer in the medicated group: 4(3–6) days compared to 2(1–4) (p < 0.0001). By type of medication, time to surgery was: 3(1–4) days for acetylsalicylic acid (n = 44), 6(5.25–7.75) days for clopidogrel (n = 15), 4.5(4–7) days for acenocoumarin (n = 18) and 5(4–7.25) days for novel direct oral anticoagulants (n = 13). The Charlson comorbidity index was significantly higher in the medicated group: 5 [4–5] versus 4 [3–5]. There were no differences in transfusions except for fresh frozen plasma, which was administered more in the medicated patients; Conclusions: the prevalence of platelet aggregation inhibitors and anticoagulant use among fragility hip fracture patients is high, with almost a third using some form of antithrombotic medication. This may significantly lengthen time to surgery.